Zoonotic Influenza Vaccine Seqirus (zoonotic influenza vaccine (H5N8) (surface antigen, inactivated, adjuvanted))
- Region
- 🇪🇺 EU
- Active substance
- zoonotic influenza vaccine (H5N8) (surface antigen, inactivated, adjuvanted)
- Company
- Seqirus S.r.l.
- Status
- Authorised
- Therapeutic area
- Influenza A Virus, H5N8 Subtype
- EU approval
- Mon 09 Oct 2023
- Application
- EMEA/H/C/006375
- ATC
- J07BB02
- Official record
- www.ema.europa.eu
Indication
Zoonotic Influenza Vaccine Seqirus H5N8 is indicated for active immunisation against H5 subtype influenza A viruses in individuals 6 months of age and above. The use of this vaccine should be in accordance with official recommendations.
Regulatory milestones
No milestones recorded in the last year.
Follow Zoonotic Influenza Vaccine Seqirus
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.